Lingotto Investment Management LLP Buys 1,255,980 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Lingotto Investment Management LLP grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 34.2% in the fourth quarter, Holdings Channel reports. The fund owned 4,931,057 shares of the company’s stock after acquiring an additional 1,255,980 shares during the quarter. Recursion Pharmaceuticals accounts for about 0.4% of Lingotto Investment Management LLP’s portfolio, making the stock its 25th largest position. Lingotto Investment Management LLP’s holdings in Recursion Pharmaceuticals were worth $20,168,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. International Assets Investment Management LLC bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $31,000. Allworth Financial LP grew its position in shares of Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares during the period. Sequoia Financial Advisors LLC bought a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $41,000. IFP Advisors Inc grew its position in shares of Recursion Pharmaceuticals by 81.5% during the 3rd quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock valued at $51,000 after acquiring an additional 4,650 shares during the period. Finally, Savant Capital LLC bought a new position in shares of Recursion Pharmaceuticals during the 3rd quarter valued at approximately $54,000. 89.06% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 30,000 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $3.52, for a total value of $105,600.00. Following the sale, the director directly owned 6,199,863 shares in the company, valued at $21,823,517.76. This represents a 0.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ben R. Taylor sold 7,956 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $3.39, for a total transaction of $26,970.84. Following the completion of the sale, the chief financial officer owned 1,180,318 shares in the company, valued at $4,001,278.02. This represents a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 96,254 shares of company stock worth $320,369 in the last three months. 8.43% of the stock is currently owned by corporate insiders.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $3.79 on Tuesday. The stock has a market capitalization of $2.01 billion, a P/E ratio of -3.16 and a beta of 1.04. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $3.28 and its 200 day moving average is $3.84. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The company had revenue of $6.47 million for the quarter, compared to analysts’ expectations of $15.78 million. During the same period in the prior year, the company posted ($0.50) EPS. Recursion Pharmaceuticals’s revenue was down 56.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.02 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Morgan Stanley increased their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Bank of America reduced their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. JPMorgan Chase & Co. dropped their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Finally, Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.10.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.